Trial Profile
A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 08 Nov 2020
Price :
$35
*
At a glance
- Drugs QPI 1007 (Primary)
- Indications Optic nerve disorders
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Quark Pharmaceuticals
- 14 Jul 2019 This trial has been completed in Germany.
- 12 Jul 2019 Status changed from recruiting to discontinued.
- 22 Oct 2018 According to a Quark Pharmaceuticals media release,data from this study will be presented at ASN 2018 and AAO 2018 Annual Meetings.